AGREENA
30.3.2023 08:01:28 CEST | Business Wire | Press release
Climate and fintech company Agreena, whose soil carbon platform is one of the largest globally, today announced its Series B raise of €46M. Led by Germany’s leading multi-stage investor HV Capital, the round has an exciting composition of new investors including impact fund AENU and fintech-focused Anthemis. The equity raise is also supported by a doubling-down from existing shareholders, including evergreen food investor Gullspång Re:food, well-established tech investor Kinnevik and Denmark’s Export and Investment fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005976/en/
Agriculture-based carbon removals are considered one of the most readily available and easily scaled solutions for climate change mitigation (Photo: Business Wire)
The sizable raise comes just one year after the company’s €20M Series A. Since then, Agreena has scaled its activities 10X, expanded its geographic footprint to cover farmland in 16 European countries, and partnered with farms to help them transition more than 600,000 hectares towards climate-positive, regenerative farming.
“In order for the world’s farmers to transition to regenerative agriculture and create a scalable climate impact, the financial rails to support and pay them for it need to be built,” said Simon Haldrup, Co-founder and CEO of Agreena. “Agreena is building out technological and financial services infrastructure throughout the agriculture value chain as the industry increasingly becomes a focal point for decarbonisation efforts.”
Momentum around regenerative farming is sweeping the globe, with corporates, governments and supply chains turning their focus to our agricultural soils for carbon removals in order to meet global net-zero targets. Through the adoption of regenerative agriculture practices, farmers will play an increasingly essential role in tackling climate change, food insecurity, and other critical environmental issues. Agreena has developed a way to turn this impact into a new and additional revenue stream for farmers to help finance the transition by leveraging the carbon market.
Via the company’s digital platform, farmers plan, track and validate improvements for their regenerative journey, in the process transitioning from emitting CO2 to drawing CO2 down and storing it within their soils. The improved soil health and biodiversity reduce the need for inputs while enhancing farmers’ resilience to increasingly adverse climate conditions (such as drought or flooding), enhancing the overall operational performance of farms. On the other side of the equation, Agreena’s certificates and downstream services support climate-focused companies already working to decarbonise, as well as companies in the food supply chain increasingly requiring field-level traceability of their agricultural commodities to comply with Scope 3 reporting requirements.
Scaling with Technology
The recent acquisition of remote sensing company Hummingbird Technologies has enabled Agreena to expand its offering beyond farmers to encompass agridata services for supply chain players, governments and other institutions. Prioritising a science-based and technology-first agenda, Agreena’s platform now incorporates a world-leading, AI-based monitoring and verification solution that utilises satellite imagery, coupled with ground-truth data and machine learning to identify and report on-farm regenerative agriculture practices. Offering global monitoring, the company is on a mission to take the lead in supporting the road to net zero for the full value chain.
“Real climate impact is only created at scale and Agreena is perfectly positioned to distribute their carbon farming capabilities across the globe to bring high-quality, verifiable and nature-based carbon credits to the market. Only with carbon removals, can net zero targets be met,” said Alexander Joel-Carbonell, partner at HV Capital.
From Farmer to Fintech
Deeply rooted within the agricultural community, Agreena was originally founded with seed investment from Danish farmers and agricultural families. The company’s next phase introduces a vertically integrated platform and marketplace. Working first with farmers in the field to monitor the carbon impact, the resulting certificates are constructed into scalable portfolios for corporates, tailored to their unique ESG strategy.
The company is taking a lead in providing the technological rails for the growing market with innovative financial solutions. Examples include using sustainable blockchain technology for enhanced traceability and transparency of carbon credits, and e-money and smart contracts to facilitate payment exchanges between climate-conscious corporates and farmers with immediate reconciliation at scale.
“We are on a journey to remove the economic barriers to adoption of regenerative agriculture for farmers and their entire ecosystem - carbon is just the beginning,” concluded Haldrup.
About Agreena
Agreena unlocks the power of soil carbon removals and natural capital to finance the transition to regenerative agriculture. Working in close collaboration with partner farmers across 16 European markets and growing, AgreenaCarbon is the world’s leading soil carbon platform. Combined with market leading satellite monitoring technologies, Agreena’s solutions can support farmers, companies, and governments on the road to net zero.
About Agreena’s Carbon Certification
Agreena’s programme is accredited to the ISO 14064-2 standard, with a third-party verified methodology that is aligned to IPCC science. The company is standards-inclusive and will continue to evolve its offering as policies and science continue to develop. Further, the company is currently undergoing certification with Verra, completion of the process is expected later this year.
About HV Capital
HV Capital is one of the most successful and financially strongest early-stage and growth investors in Europe. Since 2000, HV Capital has invested in around 225 internet and technology companies such as Zalando, Delivery Hero, Flixbus, and HelloFresh through various generations of funds and is continuously looking for the next generation of disruptors from every industry, including FinTech, SaaS, climate tech, and consumer goods. The company supports startups with capital between €500,000 to €50 million and is one of the few venture capital firms in Europe that can finance startups through all growth phases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005976/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
